GlassScriptPhysician profile
Gino Divittorio
NPI 1366456295
$139,262.55
in general payments reported to CMS, 2019-2025
28 companies · $812 in 2025
The $812 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $14K · 2021: $14K · 2022: $26K · 2023: $11K · 2024: $1,890 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,450 · Food and Beverage: $3,960 · Travel and Lodging: $934 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,450.00 |
| Food and Beverage | $3,959.59 |
| Travel and Lodging | $934.13 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95,767.94 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $29,252.09 | 2019-2024 | |
| Pfizer International LLC | $7,287.54 | 2019 | |
| Amgen INC. | $1,546.18 | 2019-2025 | Otezla, Enbrel, Otezla |
| Janssen Biotech, INC. | $1,169.17 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,104.36 | 2019-2025 | |
| Ucb, INC. | $726.94 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $575.00 | 2019-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $539.11 | 2019-2025 | Benlysta |
| Radius Health, INC. | $171.21 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $167.82 | 2019-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $132.29 | 2021-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $129.36 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $117.76 | 2022-2025 | Saphnelo |
| Celgene Corporation | $97.37 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $70.35 | 2022-2024 | Octagam Immune Globulin (Human) |
| Sanofi-Aventis U.S. LLC | $66.53 | 2019 | |
| Organon LLC | $59.30 | 2023-2024 | Hadlima |
| Horizon Therapeutics Plc | $44.98 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $44.35 | 2024 | Arcalyst |
| Sandoz INC. | $34.81 | 2023-2024 | Hyrimoz |
| Genentech USA, INC. | $31.09 | 2019 | |
| Sobi, INC | $29.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.23 | 2025 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $21.47 | 2019 | |
| Novo Nordisk INC | $17.73 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.44 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.36 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gino Divittorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.